Question 1

Is tirzepatide better than semaglutide?

Accepted Answer

For weight loss outcomes, yes — head-to-head trials show tirzepatide producing larger weight loss than semaglutide at maximum doses (~21% vs ~15% over a comparable timeframe). The dual GIP+GLP-1 mechanism appears to drive deeper satiety and additional metabolic effects. That doesn't make it the right choice for everyone. Side-effect tolerability varies by individual; some patients do better on semaglutide. Cost and supply can also drive the decision — both are expensive, and both have been subject to shortages.

Question 2

What is the difference between Mounjaro and Zepbound?

Accepted Answer

Same molecule, different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Identical drug, identical dosing — the difference is on the label, which affects insurance coverage and pharmacy distribution.

Question 3

How much weight will I lose?

Accepted Answer

On the maximum 15 mg weekly dose, average weight loss in trials was ~21% of body weight over 72 weeks. Individual responses vary widely — some patients lose 25–30%, others under 10%. Adherence, dose escalation tolerability, baseline metabolic state, and lifestyle changes all matter. Most clinics use 5–10 mg as a target maintenance dose, not the maximum 15 mg. The trade-off is fewer side effects vs. peak weight-loss outcomes.

Question 4

Do I have to stay on it forever?

Accepted Answer

The honest answer is: probably long-term, if you want to maintain the weight loss. Obesity is a chronic metabolic condition — when you stop the drug, the underlying physiology that produced the obesity is still there, and weight tends to return. Some patients do successfully transition to maintenance protocols (lower dose, less frequent dosing, or supportive non-pharmaceutical strategies). That conversation happens with your provider after you reach your goal.

Question 5

What are the most common side effects?

Accepted Answer

Nausea, constipation, diarrhea, reflux, and reduced appetite — all of which are dose-dependent and typically peak during the titration phase. About 5% of patients in trials discontinued due to GI symptoms. More serious but less common: gallbladder events (cholecystitis, stones), pancreatitis, severe vomiting requiring hydration. Discuss with your provider if you have a personal history of any of these.

Tirzepatide (Mounjaro / Zepbound) in Dallas, TX

Benefits

Larger weight loss

Improved metabolic markers

Better appetite control

How it works

Initial consultation

Baseline labs

Personalized protocol

Ongoing follow-up

Designed around your schedule

Dallas clinics on the map

Where to get it

Primary One Care

Provider offering this service

Upsize Dallas

Providers offering this service

Patient reviews in Dallas

What sets us apart

Talk to a Dallas physician about tirzepatide (mounjaro / zepbound).